Use of a new delayed-release anhydrous theophylline by single daily administration in the treatment of reversible bronchial obstruction. Comparison with a delayed-release preparation administered twice daily
Baronti, A.; Verdiani, P.; Di Carlo, S.
La Clinica Terapeutica 122(6): 437-440
1987
ISSN/ISBN: 0009-9074 PMID: 2972456 Document Number: 292714
The pharmacokinetics, therapeutic activity, tolerability and side effects of a slow-release theophylline administered at the once-daily morning dosage of 700 mg were assessed in 16 patients suffering from chronic obstructive lung disease. A slow-release product for which twice-daily administration of 300 mg was advised was given as reference drug. Contrary of the latter (which in 3 subjects gave rise to peak concentrations over 20 mcg/ml) the test preparation induced peal concentrations below 20 mcg/ml in all patients. The fluctuation index was higher for the test preparation compared to the reference drug but was within acceptable limits and always wthin the therapeutic range. In addition, the coefficient of variability between patients for average serum concentration was lower for the test drug while efficacy and tolerability were the same for both. The test drug is therefore suitable for once-daily administration.